



Supplementary Figure 2. Ototoxicity of different CDs as assessed by ABR recordings. (A) ABR thresholds evaluated in 8-week-old mice, 18-24 hours post-injection. (B) ABR thresholds evaluated in 28-week-old mice, after 20 CD injections given once weekly. Differences between treatment groups are similar to those observed after 4 weeks of CD injections (see Fig 5), suggesting that adverse effects on hearing are not progressive and that sustained treatment with the SBE-CDs or HPαCD does not lead to ototoxicity.